Jennifer L. Taubert于2005年加入公司，担任公司子公司Johnson&Johnson Pharmaceutical Services的全球副总裁。2012年，她被任命为公司集团北美制药公司董事长，并于2015年成为公司集团美洲制药公司董事长。2018年7月，Taubert女士晋升为执行副总裁、全球制药公司董事长，并成为执行委员会成员。

Jennifer L. Taubert was appointed Executive Vice President, Worldwide Chairman, Innovative Medicine and a member of the Executive Committee in 2018. She joined the Company in 2005 as Worldwide Vice President and held several executive positions of increasing responsibility in the Pharmaceuticals sector, including Company Group Chairman, North America, and Company Group Chairman, The Americas from 2012 2018.

Tim Schmid，于2023年10月被任命为医疗技术执行副总裁兼全球董事长，并被任命为执行委员会成员。他于1993年加入强生公司，曾在强生MedTech公司担任领导职务，包括首席战略客户官兼Ethicon总裁，最近于2018-2023年担任公司集团董事长MedTech亚太区。

Tim Schmid was appointed Executive Vice President, Worldwide Chairman, MedTech and a member of the Executive Committee in 2023. He joined the Company in 1993 and has served in leadership positions throughout Johnson & Johnson MedTech, including Chief Strategic Ctomer Officer and President of Ethicon, and most recently served as Company Group Chairman MedTech Asia Pacific from 2018 2023.

Joaquin Duato，于1989年加入Johnson & Johnson，任职Janssen-Farmaceutica S.A. Spain，并于1997年成为Janssen-Cilag S.p.A。（位于意大利）的董事总经理。他于2000年领导了Ortho Biotech Europe，并在2002年迁往美国，担任副总裁，并于2005年担任Ortho Biotech Inc.的总裁。他于2008年被任命为公司集团董事长，负责Ortho临床诊断，并于2009年担任公司集团制药董事长，在那里他曾在加拿大、美国和拉丁美洲监督药品产品的发布和主要治疗特许经营。他于2011年被任命为全球制药主席，负责Janssen Pharmaceutical公司的全球商业业务，包括为研究和开发组织提供功能支持。他于2016年4月成为执行委员会成员，并被任命为执行副总裁、全球董事长，负责制药。

Joaquin Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022. Mr. Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee. Mr. Duato first joined the Company in 1989 with Janssen Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all biness sectors and across multiple geographies and functions.

Kathryn E. Wengel于1988年加入公司，担任公司子公司Janssen的项目工程师和工程监理。在公司任职期间，她在全球企业内担任各种战略领导和执行职务，在运营、质量、工程、新产品、信息技术以及其他技术和业务职能部门担任职务。2010年，温格尔女士成为该公司的第一位首席质量官。2014年，她被提升为强生供应链副总裁。2018年7月，她被提升为执行副总裁、全球供应链总监，并成为执行委员会成员。

Kathryn E. Wengel has served as a director of the Company since March 2021. Ms. Wengel has served as the Executive Vice President, Chief Technical Operations & Risk Officer of Johnson & Johnson, a leading healthcare company, since January 2023 and as an Executive Committee member and an Executive Officer of Johnson & Johnson since July 2018. Ms. Wengel has significant healthcare, operations, and global business expertise, with more than three decades of experience in leadership positions at Johnson & Johnson in the United States and various locations globally, including as its Worldwide Vice President and then Executive Vice President, Chief Global Supply Chain Officer from March 2014 to December 2022, and its first Chief Quality Officer from April 2010 to March 2014. Ms. Wengel holds a Bachelor of Science in civil engineering and operations research from Princeton University.

James Swanson，于2019年从拜耳作物科学公司（Bayer Crop Science）重新加入公司，担任强生公司首席信息官。他曾在拜耳作物科学公司担任高管领导团队成员、首席信息官和数字转型主管。从1996年到2005年，Swanson在公司担任越来越重要的职务，包括项目经理、IT总监、高级IT总监和副总裁、首席信息官。Swanson先生负责增强强生公司的业务影响力，并通过战略性地使用技术来塑造公司的发展方向。执行副总裁兼首席信息官斯旺森先生于2022年1月3日加入执行委员会。

James Swanson was appointed Executive Vice President, Chief Information Officer and a member of the Executive Committee in 2022. He rejoined the Company in 2019 as Chief Information Officer of Johnson & Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as Chief Information Officer and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer.

Elizabeth Forminard于2006年加入Johnson & Johnson公司，担任消费者保健全球业务部法律副总裁，并继续担任越来越重要的职务。2012年，她被提升为医疗设备和诊断部门的总法律顾问，并于2013年成为消费者集团和供应链部门的总法律顾问。2016年，她被任命为公司治理全球副总裁。2019年至2022年，她担任制药总法律顾问。2022年10月，她被任命为执行副总裁兼总法律顾问，并成为执行委员会成员。Forminard女士在全球范围内负责法律和隐私职能，并领导公司环境、社会和治理战略的制定和执行。

Elizabeth Forminard was appointed Executive Vice President, Chief Legal Officer and a member of the Executive Committee in 2022. Ms. Forminard joined the Company in 2006, serving in roles of increasing responsibility including General Counsel Medical Devices & Diagnostics, General Counsel Consumer Group & Supply Chain, Worldwide Vice President Corporate Governance, and in her immediate past role as General Counsel Pharmaceuticals.

Joseph J. Wolk，他将担任Kenvue Inc.的董事，在本次发行完成之前生效。Wolk先生自2018年起担任Johnson & Johnson的执行副总裁兼首席财务官。他还担任Johnson & Johnson的执行委员会成员。Wolk先生此前在强生公司（Johnson & Johnson）的24年里担任多个部门和职能部门的各种高级领导职务，包括投资者关系副总裁、制药集团财务副总裁、医疗设备全球供应链财务副总裁和北美制药集团首席财务官。他还是Johnson & Johnson影响风险基金和退伍军人领导力委员会的执行发起人，并支持Johnson & Johnson的财务领导力发展计划。他任职于St. Joseph's University Board of Trustees，是Stanford Medicine Board of Fellows、CNBC Global CFO Council和the Wall Street Journal CFO Network的成员。他持有St. Joseph's University的金融学士学位和Temple University School of Law的法学博士学位。

Joseph J. Wolk has been the Executive Vice President and CFO of Johnson & Johnson (a multinational pharmaceutical, biotechnology, and medical technologies corporation) since 2018. He is also a member of Johnson & Johnson's Executive Committee and was the sponsor overseeing all capital markets and operational aspects of the separation of the Company's Consumer Health biness into an independent, publicly traded company, Kenvue. He served on the Kenvue board from 2023 to 2024 while Johnson & Johnson held an equity interest in the company. Previoly, Mr. Wolk served in vario leadership positions at Johnson & Johnson as ll as at AMETEK, Inc. in a variety of accounting roles.

Kristen Mulholland，被任命为执行副总裁、首席人力资源官，并于2024年被任命为执行委员会成员。她于2005年加入公司，并在公司的各个部门担任人力资源领导职位，包括医疗技术、创新药品、强生公司职能和企业人力资源服务（包括绩效和发展），以及最近的全球总奖励。

Kristen Mulholland was appointed Executive Vice President, Chief Human Resces Officer and appointed to the Executive Committee in 2024. She joined the company in 2005 and has held HR leadership positions across the full breadth of the company including MedTech, Innovative Medicines, Corporate Functions and Corporate HR Services including Performance and Development and most recently, Global Total Rewards.

John C. Reed，于2023年加入公司，担任创新医学、研发执行副总裁和执行委员会成员。在加入公司之前，Reed博士曾在赛诺菲（2018-2022年）和罗氏（2013-2018年）担任行政领导职务，在各自的执行委员会任职。他还曾担任Sanford-Burnham Medical Research Institute（现为Sanford Burnham Prebys）的首席执行官，在那里他建立了多个与治疗区域一致的研究中心和平台技术中心。

John C. Reed joined the Company in 2023 as Executive Vice President, Innovative Medicine, R&D and a member of the Executive Committee. Prior to joining the Company, Dr. Reed held executive leadership positions at Sanofi (2018 2022) and Roche (2013 2018), serving on their respective executive committees. He also served as CEO of Sanford Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area aligned research centers and platform technology centers.

Vanessa Broadhurst目前在强生担任全球企业事务执行副总裁，强生公司是一家专注于与人类健康和福祉相关的产品的全球性公司，她还是强生公司执行委员会的成员。在强生，Broadhurst女士领导公司的企业营销、全球传播、健康与保健解决方案、全球公共卫生和慈善职能。任职期间，布罗德赫斯特女士的职责包括领导大量员工的人力资本管理。在2023年Kenvue从强生分离出消费者之前，她还领导过消费者沟通、设计，包括包装，以及产品设计。在目前任职于强生之前，Broadhurst女士曾于2019年至2021年12月担任公司集团主席、全球医药商业战略，并于2017年至2018年担任心血管和代谢领域总裁。在加入强生之前，Broadhurst女士在安进担任心血管和骨骼业务部门总经理（2014-2017年），任职期间，她在并购活动、管道开发和新产品发布战略方面担任领导职务。此前她曾在安进担任炎症和心血管事业部总经理（2013-2014年）。从2005年到2013年，布罗德赫斯特女士在强生担任过多个高级领导职务。在2005年之前，Broadhurst女士曾担任诺华公司全球胃肠病学市场营销主管（2003-2005年），并在雅培担任过各种职务，承担着越来越大的责任（1994-2003年）。Broadhurst女士担任执行领导委员会（ELC）成员和AD委员会董事会成员。她获得了密歇根大学罗斯商学院的工商管理硕士学位，她是学院的财团研究员，并获得了科罗拉多大学博尔德分校的文学学士学位。Broadhurst女士在消费者医疗保健营销和数字传播方面的专长，以及她在全球制药行业的业务经验，使她成为硕腾公司董事会的宝贵成员。

Vanessa Broadhurst was named Executive Vice President, Global Corporate Affairs and appointed to the Executive Committee in 2022. Ms. Broadhurst rejoined the Company in 2017 and was appointed Company Group Chairman, Global Commercial Strategy Organization in 2018. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation & Cardiovascular, and Cardiovascular & Bone. Prior to her roles at Amgen, she served in vario leadership roles at the Company from 2005 2013.

Joaquin Duato，于1989年加入Johnson & Johnson，任职Janssen-Farmaceutica S.A. Spain，并于1997年成为Janssen-Cilag S.p.A。（位于意大利）的董事总经理。他于2000年领导了Ortho Biotech Europe，并在2002年迁往美国，担任副总裁，并于2005年担任Ortho Biotech Inc.的总裁。他于2008年被任命为公司集团董事长，负责Ortho临床诊断，并于2009年担任公司集团制药董事长，在那里他曾在加拿大、美国和拉丁美洲监督药品产品的发布和主要治疗特许经营。他于2011年被任命为全球制药主席，负责Janssen Pharmaceutical公司的全球商业业务，包括为研究和开发组织提供功能支持。他于2016年4月成为执行委员会成员，并被任命为执行副总裁、全球董事长，负责制药。

Joaquin Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022. Mr. Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee. Mr. Duato first joined the Company in 1989 with Janssen Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all biness sectors and across multiple geographies and functions.

J. A. Doudna于2002年加入加州大学伯克利分校，担任生物化学和分子生物学教授。她是加州大学伯克利分校和旧金山分校联合中心创新基因研究所的负责人，拥有李嘉诚校长生物医学与健康教授职位，是加州大学伯克利分校校长生物咨询委员会主席。Doudna博士是加州大学伯克利分校Doudna实验室的主要研究人员，曾在驯鹿生物科学公司（Caribou Biosciences，Inc.）和Intellia Therapeutics，Inc.的科学咨询委员会任职，这两家都是领先的CRISPR基因组工程公司。自1997年以来，她一直是霍华德休斯医学研究所的研究员。Doudna博士是众多生物化学和遗传学科学奖的获得者，包括2020年的诺贝尔化学奖。杜德纳博士是波莫纳学院的受托人。

J. A. Doudna, joined the faculty at University of California, Berkeley, as a Professor of Biochemistry & Molecular Biology in 2002. She directs the Innovative Genomics Institute, a joint UC Berkeley-UC San Francisco center, holds the Li Ka Shing Chancellor's Professorship in Biomedical and Health and is the Chair of the Chancellor's Advisory Committee on Biology at UC Berkeley. Dr. Doudna is Principal Investigator at the Doudna Lab at UC Berkeley and has founded and serves on the Scientific Advisory Boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies. She has been an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Nobel Prize in Chemistry in 2020. Dr. Doudna is a Trustee for Pomona College.

Eugene A. Woods，Atrium Health公司总裁兼首席执行官，2016年至今。Christus Health公司总裁兼首席运营官，2014年至2015年；2011-2014年Christus Health执行副总裁兼首席运营官；2005-2011年圣约瑟夫天主教健康保健倡议高级副总裁、运营和首席执行官；2001-2005年华盛顿医院中心高级副总裁兼首席运营官；罗伊施耐德医院院长兼首席执行官（1998-2001）；罗伊施耐德医院院长兼首席执行官（1998-2001）；Woods先生持有宾夕法尼亚州立大学多个学位。

Eugene A. Woods,Chief Executive Officer of Advocate Health (2022-present);President and Chief Executive Officer of Atrium Health (2016-2022);President and Chief Operating Officer of Christus Health (2014-2015);Executive Vice President and Chief Operating Officer of Christus Health (2011-2014);Senior Vice President, Operations and Chief Executive Officer of St. Joseph Health Care for Catholic Health Initiatives (2005-2011);Senior Vice President and Chief Operating Officer of Washington Hospital Center (2001-2005);President and Chief Executive Officer of Roy Schneider Hospital (1998-2001); and Vice President, Administration at Southside Regional Medical Center (1993-1998).Mr. Woods attended Pennsylvania State University, where he earned a bachelor's degree and two master's degrees.

Marillyn A. Hewson，从2020年6月到2021年3月担任Lockheed Martin Corporation aerospace的执行主席，从2014年6月到2020年6月担任董事长、总裁兼首席执行官，从2013年1月到12月担任首席执行官兼总裁。Hewson女士从2012年到2021年3月担任Lockheed Martin Corporation的董事。Hewson女士目前任职于阿拉巴马大学总统内阁和卡尔弗豪斯商学院访客委员会。此外，她还是美国航空航天研究所的研究员和三边委员会的成员。Hewson女士还曾在多个美国政府咨询机构、上市公司董事会和慈善组织董事会任职。

Marillyn A. Hewson served as the Executive Chairman of Lockheed Martin Corporation aerospace from June 2020 until March 2021 as Chairman, President and Chief Executive Officer from 2014 to June 2020 and held the positions of Chief Executive Officer and President from January to December 2013. Ms. Hewson served as a Director of Lockheed Martin Corporation from 2012 through March 2021. Ms. Hewson currently serves on the University of Alabama President's Cabinet and the Culverhouse College of Business Board of Visitors. In addition, she is a fellow of the American Institute of Aeronautics and Astronautics and a member of the Trilateral Commission. Ms. Hewson has also served on several U.S. government advisory bodies, public company boards, and charitable organization boards.

H. Joly于2019年6月至2020年6月担任百思买消费电子有限公司（Best Buy Co.，Inc.）执行董事长，2012年加入百思买，担任总裁兼首席执行官，2015年出任百思买董事长、总裁兼首席执行官。2004年至2008年，他担任卡尔森华高利特旅行社（Carlson Wagonlit Travel）全球总裁兼首席执行官，然后在2008年至2012年期间担任卡尔森公司总裁兼首席执行官。1999年，他加入维旺迪，担任维旺迪环球运动会全球首席执行官，后来被任命为美国资产执行副总裁和维旺迪环球副首席财务官。1996年至1999年担任欧洲副总裁兼法国电子数据系统总裁，1983年至1996年担任麦肯锡公司合伙人。Joly先生是哈佛商学院（Harvard Business School）的工商管理高级讲师，曾任职于Sciences Po Foundation董事会、明尼阿波利斯艺术学院董事会和母校巴黎高等商学院国际咨询委员会。

H. Joly,served as the Executive Chairman of Best Buy Co., Inc. (consumer electronics) from June 2019 to June 2020, having joined the company in 2012 as President and Chief Executive Officer and becoming Chairman, President and Chief Executive in 2015. From 2004 to 2008, he was Global President and Chief Executive Officer, Carlson Wagonlit Travel, and then served as President and Chief Executive Officer of Carlson Companies from 2008 to 2012. In 1999, he joined Vivendi as Global Chief Executive Officer, Vivendi Universal Games, and was later appointed Executive Vice President of U.S. Assets and Deputy Chief Financial Officer of Vivendi Universal. Prior roles included, from 1996 to 1999, Vice President, Europe and President of Electronic Data Systems France and, from 1983 to 1996, McKinsey & Company, eventually serving as Partner. Mr. Joly is a Senior Lecturer of Business Administration at Harvard Business School and serves on the Board of Directors of Sciences Po Foundation, the Board of Trustees of the Minneapolis Institute of Art, the New York Public Library and the International Advisory Board of his alma mater, HEC Paris.

M. A. Weinberger于2013年至2019年6月担任EY Ernst&Young（专业服务）的全球董事长兼首席执行官，前一年担任全球董事长和首席执行官。他曾任乔治·布什政府美国财政部助理秘书，由克林顿总统任命为美国社会保障行政咨询委员会成员。M. A. Weinberger先生是斯通峡谷工业控股公司和特内诺的高级顾问。他是G100和世界50的执行顾问。温伯格先生还担任FCLTGlobal董事会的战略顾问，FCLTGlobal董事会的重点是长期投资和公司治理。M. A. Weinberger先生是正义资本的首席执行官咨询委员会成员。他担任国家经济研究局（NBER）董事会成员，是公司目标首席执行官的高级顾问，是Aspen经济战略集团的成员。他是埃默里大学、凯西储备大学、协和联盟、大华盛顿伙伴关系和美国国际商务理事会董事会成员。

M. A. Weinberger,served as the Global Chairman and Chief Executive Officer of EY (Ernst & Young) (professional services) from 2013 through June 2019, having served as Global Chairman and CEO-elect in the prior year. He was Assistant Secretary of the U.S. Treasury in the George W. Bush Administration and was appointed by President Bill Clinton to serve on the U.S. Social Security Administration Advisory Board. Mr. Weinberger serves as a Senior Advisor to Stone Canyon Industries Holdings Inc. and Teneo. He is an Executive Advisor to G100 and World 50. Mr. Weinberger also serves as a Strategic Advisor to the Board of FCLTGlobal, which focuses on long-term investing and corporate governance. Mr. Weinberger is on the CEO Advisory Council of JUST Capital. He sits on the Board of Directors of the National Bureau of Economic Research (NBER), is a Senior Advisor to Chief Executives for Corporate Purpose (CECP) and is a member of the Aspen Economic Strategy Group. He is a member of the Boards of Trustees for Emory University, Case Western Reserve University, The Concord Coalition, The Greater Washington Partnership and US Council for International Business.

Nadja Y. West，服役37年后以中将军衔从美国陆军退役。2015年至2019年，West将军担任第44任美国陆军外科医生兼美国陆军医疗司令部司令。在此之前，West将军从2013年到2015年担任联合参谋部外科医生，担任参谋长联席会议主席的首席医疗顾问。她还曾担任欧洲区域医疗司令部司令和布拉格堡沃马克陆军医疗中心司令。她是许多军事奖项的获得者，包括杰出服务奖章，国防高级服务奖章和功绩军团。West将军是国防部自杀预防和反应独立审查委员会的顾问。她还担任Johnson & Johnson和Tenet Healthcare Corporation的董事。

Nadja Y. West retired from the U.S. Army with the rank of Lieutenant General after serving for 37 years. From 2015 to 2019, General West served as the 44th U.S. Army Surgeon General and Commanding General of the U.S. Army Medical Command. Prior to that, General West served as Joint Staff Surgeon from 2013 to 2015, acting as the chief medical advisor to the Chairman of the Joint Chiefs of Staff. She also previously served as Commanding General of Europe Regional Medical Command and Commander of Womack Army Medical Center at Fort Bragg. She is the recipient of numerous military awards, including the Distinguished Service Medal, the Defense Superior Service Medal and the Legion of Merit. General West recently served as a consultant to the Department of Defense Suicide Prevention and Response Independent Review Committee.

Mark B. McClellan于2016年1月成为Duke Robert J.Margolis，健康政策中心的首任主任和杜克大学商业、医学和政策的Margolis教授。此前，他曾在2007年至2015年担任经济研究高级研究员，并担任Brookings Institution医疗保健价值与创新倡议主任。McClellan博士在2004年至2006年期间担任美国卫生和公众服务部医疗保险和医疗补助服务中心的管理员，并在2002年至2004年期间担任美国食品和药物管理局的专员。2001年至2002年，他曾任总统经济顾问委员会成员和白宫医疗政策高级主管，1998年至2000年，他曾任财政部负责经济政策的副助理部长。McClellan博士获得德克萨斯大学文学学士学位，哈佛大学公共管理硕士和医学博士学位，麻省理工学院经济学哲学博士学位。

Mark B. McClellan became the inaugural Director of the Duke Robert J. Margolis, M.D., Institute for Health Policy and the Margolis Professor of Biness, Medicine, and Policy at Duke University in January 2016. He currently serves in vario leadership and advisory capacities for the National Academy of Medicine, and other nonprofit organizations. He also was the founding Chair of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA). Dr. McClellan is a two time recipient of the Kenneth Arrow Award for Outstanding Research in Health Economics.Additionally, Dr. McClellan was at the center of U.S. efforts to combat the COVID 19 pandemic and co authored a road map and other publications for a comprehensive response and safe reopening. His ongoing collaborative research programs are developing policy reforms and support for resilient models of delivering better, more equitable care to address population health challenges; for more efficient development and effective e of innovative medicines, through better evidence on outcomes; and for accelerating applications of digital and AI technologies that improve health care access and affordability.PhD, Massachetts Institute of Technology;MD, Harvard MIT Division of Health Sciences and Technology;MPA, Harvard University;BA, University of Texas.

John Morikis，2016年至2024年担任Sherwin-Williams Company执行董事长、总裁兼首席执行官。他于1984年加入Sherwin-Williams，担任Paint Stores Group的管理培训生。2006年至2016年，Morikis先生担任总裁兼首席运营官。

John Morikis,served as the Executive Chairman, President and Chief Executive Officer of The Sherwin-Williams Company from 2016 to 2024. He joined Sherwin-Williams in 1984 as a management trainee in the Paint Stores Group.From 2006 to 2016, Mr. Morikis served as President and Chief Operating Officer.

Daniel Pinto，现任摩根大通总裁，并将于2025年7月1日至2026年底退休期间担任副董事长。在此之前，他在摩根大通任职期间担任首席运营官等职务。

Daniel Pinto,currently serves as the President of JPMorganChase and will serve as Vice Chairman of the firm from July 1, 2025 through his retirement at the end of 2026. He previously served as Chief Operating Officer, among other roles, during his tenure at the firm.

Paula A. Johnson自2016年起担任韦尔斯利学院校长。她是一名专门研究心脏病的医师-研究员，曾于2002年7月至2016年6月在布莱根妇女医院创立并担任康纳斯妇女健康和性别生物学中心的首任执行主任。Johnson博士于2002年7月至2016年6月担任布莱根妇女医院妇女健康处处长。她还是哈佛医学院的医学教授和哈佛公共卫生学院的流行病学教授。她拥有哈佛大学文学士、医学博士和公共卫生硕士学位，并在布莱根妇女医院接受内科和心血管内科培训。

Paula A. Johnson has served as the president of Wellesley College since 2016. She is a physician-researcher specializing in cardiology who founded and served as the inaugural Executive Director of the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital from July 2002 to June 2016. Dr. Johnson served as the Chief of the Division of Women's Health at Brigham and Women's Hospital from July 2002 to June 2016. She was also a Professor of Medicine at the Harvard Medical School and Professor of Epidemiology at the Harvard School of Public Health. She holds a Bachelor of Arts, Doctor of Medicine and Masters in Public Health from Harvard University, and trained in internal medicine and cardiovascular medicine at Brigham and Women's Hospital.

Mary C. Beckerle自2011年5月起担任公司董事。她是公司管理委员会的成员。 Beckerle博士是国际公认的科学家，曾在众多国家科学董事会和委员会任职。她是美国国家研究院的董事以及咨询委员会的成员。她目前在美国癌症研究协会的任职。她是哈佛大学，乔治城大学，宾夕法尼亚大学，印度班加罗尔国家生物科学中心，新加坡国立大学力学生物学研究所五家癌症政策和顾问委员会的成员。Beckerle博士于1986年进入犹他大学，并担任该校生物科学院的特聘教授。Beckerle博士自2006年一直担任美国犹他州大学Huntsman癌症研究所的首席执行官和董事。 Beckerle博士曾于2006年担任美国细胞生物学协会的总裁，并在巴黎居里研究所获得古根海姆奖学金，成为美国艺术和科学学院的院士。 Beckerle博士已被任命为公司董事全国协会（NACD）的管理院士。

Mary C. Beckerle,Extensive executive, strategic, and operational experience, including overall leadership and accountability as CEO for management of a Comprehensive Cancer Center with more than 3,000 personnel and over $1 billion of annual clinical and research revenue, enables Dr. Beckerle to provide valuable strategic insights related to management, product innovation and business development to Huntsman management and the Board;Broad experience and deep knowledge base in state-of-the-art corporate governance practices, sustainability, risk management, and regulatory compliance as CEO of a world-class healthcare delivery organization and an Independent Director of Johnson & Johnson, a leading global healthcare company;Deep experience in science and technology at operational, executive management, and board oversight levels enables her to provide valuable insight and guidance related to organic and inorganic research and development opportunities and to ensure ongoing focus on innovation which fuels value generation at the Company;Chief Executive Officer (2011 - present) and Executive Director (2006 - 2011), University of Utah's Huntsman Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center;Distinguished Professor and Associate Vice President for Cancer Affairs, University of Utah (present); joined University of Utah in 1986;Guggenheim Fellow and Rothschild-Yvette Scholar at the Curie Institute, Paris, France (1999 - 2000).

Daniel Pinto从2012年7月开始担任Corporate & Investment Bank的联合首席执行官，并从2011年6月开始担任欧洲、中东与非洲地区的首席执行官。从2009年11月到2012年7月，他担任全球固定收益业务部的主管或联席主管。从2006年到2009年，他担任新兴市场部的全球负责人，从2008年到2009年，还负责管理全球信贷交易与企业联合组织的业务。

Daniel Pinto,spent more than 40 years at JPMorgan and served as sole President and Chief Operating Officer from 2022 to July 2025. Prior to that, he served as Co-President and Chief Operating Officer of JPMorgan from 2018 to 2022.Mr. Pinto led JPMorgan's Corporate & Investment Bank from 2012 to 2018. He was named Co-Chief Executive Officer of JPMorgan's Corporate & Investment Bank in 2012 and became sole Chief Executive Officer in 2014. Mr. Pinto also served as Chief Executive Officer of the Europe, the Middle East and Africa (EMEA) region from 2011 to 2017. Prior to that, Mr. Pinto held senior markets roles at JPMorgan in emerging markets, later expanding his remit to include Global Credit Trading & Syndicate and Global Fixed Income. He serves as a member of the Board of Directors of the Institute of International Finance. Mr. Pinto has served on the board of directors of Johnson & Johnson since 2025. Mr. Pinto earned a bachelor's degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires.